Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348231 | 0.90 | SCD (0.80) | SCDROCK2 | |
| SCHEMBL242074 | 0.89 | SCD (0.82) | SCDKDM4ELMNAPOLBMAPT | |
| SCHEMBL347143 | 0.86 | SCD (0.65) | SCDPIK3CDPIK3CAPIK3CBROCK2 | |
| SCHEMBL245185 | 0.85 | SCD (0.77) | SCDPIK3CDPIK3CAPIK3CBPOLB | |
| SCHEMBL13557327 | 0.83 | SCD (0.67) | SCDPIK3CDPIK3CAPIK3CBKDM4E | |
| SCHEMBL245171 | 0.83 | SCD (0.67) | SCDKDM4ELMNAPOLBRAB9A | |
| SCHEMBL243951 | 0.83 | SCD (0.73) | SCDPIK3CDPIK3CAPIK3CBKDM4E | |
| SCHEMBL246369 | 0.83 | SCD (0.72) | SCDKDM4ELMNAPOLBMAPT | |
| SCHEMBL241999 | 0.82 | SCD (0.88) | SCD | |
| SCHEMBL348110 | 0.82 | SCD (0.60) | SCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885PIK3CD 2361/4885PIK3CA 2130/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885PIK3CD 2361/4885PIK3CA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.